Virtual Library

Start Your Search

Karen Kelly



Author of

  • +

    19 - Debate #3 Optimal Therapy After Progression on Osimertinib with No New Driver is Chemotherapy Alone (ID 19)

    • Event: TTLC 2019
    • Type: General Session
    • Track:
    • Presentations: 1
    • +

      No - Chemo + IO + Bev (ID 19.01)

      18:05 - 18:20  |  Author(s): Karen Kelly

      • Abstract

      Abstract not provided

  • +

    22 - ICI Combinations (Stimulatory and Inhibitory) (ID 22)

    • Event: TTLC 2019
    • Type: General Session
    • Track:
    • Presentations: 1
    • +

      LYC55716 (RORgamma) (ID 22.18)

      08:00 - 09:50  |  Author(s): Karen Kelly

      • Abstract
      • Slides

      Abstract not provided

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.